Methods. This randomized, double-blind, placebo-controlled study was designed to compare humoral responses to licensed trivalent influenza vaccine given concomitantly with 1 of 2 RSV vaccine formulations in persons 65 years old with cardiopulmonary disease. Hemagglutinin-inhibition assays and neutralization assays were used to measure levels of antibody to influenza and RSV, respectively. Subjects with respiratory illnesses during subsequent winters were tested for RSV and influenza by reverse-transcriptase polymerase chain reaction and serologic analysis.
gens responsible for serious viral respiratory infections [8] . Despite active research on vaccine development since discovery of the virus in the 1950s, an effective vaccine remains an elusive goal [9, 10] . Although all adults have measurable levels of serum antibody to RSV, low neutralizing antibody levels are a risk factor both for infection and severe disease [11, 12] . Cellular immunity may be an important factor in limiting RSV replication and although RSV-specific data are limited, it is known that aging significantly alters cellular immunity [13] . Thus, an ideal RSV vaccine candidate for older adults might both stimulate high levels of neutralizing antibody and augment cellular immunity.
Sanofi pasteur has developed a subunit RSV vaccine containing the fusion (F) and attachment (G) surface glycoproteins and the matrix protein (M) of RSV [9, 14] . Antibodies directed against F and G proteins neutralize virus in vitro, and in animal models, the M protein may stimulate T cell responses [15] [16] [17] . Because RSV activity overlaps with seasonal influenza, an RSV vaccine would likely need to be given concurrently with influenza vaccine each winter. Thus, the primary objective of this phase II clinical study was to compare elderly individuals' humoral responses to a licensed trivalent influenza vaccine given concomitantly with 1 of 2 RSV vaccine formulations, compared with responses to the influenza vaccine given with placebo. The safety and immunogenicity of the 2 RSV vaccine formulations were also compared.
METHODS

Study Design
The trial was a randomized, double-blind, placebo-controlled study conducted over 2 years (from 2002-2004) at 38 centers throughout the United States. From September through early November of year 1, participants were randomized into 3 groups in a 1:1:1 ratio, with a block size of 6, to receive RSV vaccine adjuvanted with alum, nonadjuvanted RSV vaccine, or saline placebo. All participants received licensed inactivated trivalent influenza vaccine (Fluzone; sanofi pasteur) at the same visit in the opposite arm. On the basis of immunogenicity data from year 1, the superior RSV vaccine was selected. The subjects who initially received either the superior RSV vaccine or placebo were divided into 2 groups and vaccinated 52 weeks after their initial treatment according to their original randomization; they also received concomitant influenza vaccination. Subjects who initially received the inferior RSV vaccine formulation were not revaccinated and were no longer followed up.
Subjects
Persons with cardiopulmonary diseases are at highest risk for serious RSV disease and were therefore selected for inclusion in this trial. Study subjects were required to be 65 years old and to have a physician-confirmed diagnosis of congestive heart failure (CHF) or active pulmonary disease that required medication to control symptoms. Active pulmonary diseases included chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, asthma, interstitial fibrosis, and environmental lung disease. Participants were excluded if they had known immunodeficiency, autoimmune disease, or active malignancy, or were taking immunosuppressive medications. The study was approved by the University of Rochester research review board and all local institutional review boards. All subjects provided signed informed consent prior to enrollment.
Study Vaccines
Each RSV vaccine dose (0.5 mL) contained ϳ100 g of total protein and was formulated to contain 45 Ϯ 9 g of the RSV fusion (F) protein with 3 g of the attachment (G) protein and 15-45 g of matrix (M) protein from group A RSV. Each dose of the adjuvanted RSV vaccine also contained 1.5 mg of aluminum phosphate (alum). Influenza vaccine (Fluzone), the licensed trivalent vaccine formulated for the 2002-2003 and 2003-2004 seasons, was used in the formulation appropriate for the year it was administered. Influenza and RSV or placebo vaccinations were administered intramuscularly into the deltoid muscle in opposite arms.
Study Procedures
The immunogenicity of the influenza and RSV vaccinations was assessed at 1 month and 12 months after the year 1 and year 2 vaccinations. Immediate safety was assessed on site for 30 min after receipt of vaccination. Adverse events (AEs), both local and systemic, were solicited for 7 days after vaccination by use of diary cards. Nonsolicited adverse events were recorded for 4 weeks after vaccination, and serious adverse events (SAEs) were recorded throughout the entire study period.
Surveillance for acute respiratory illness (ARI) began 8 days after vaccination (starting in late September) and continued through the end of April in the following year. Weekly phone calls to subjects ensured that illnesses were evaluated. ARI was defined as new onset or worsening of either 2 respiratory symptoms (sore throat, nasal congestion, or discharge, hoarseness, cough, sputum, wheezing, dyspnea, or pleuritic chest pain) or 1 respiratory symptom and 1 systemic symptom (feverishness, fatigue, anorexia, headache, or myalgia). If an illness met the ARI criteria, a nasal swab sample and blood sample were collected during the acute phase of infection. Participants filled out diary cards during the illness and a convalescent-phase blood sample was collected approximately 4 weeks after the illness.
Laboratory Methods
RSV serologic analysis. Levels of serum antibody to RSV were assessed by a plaque reduction neutralization assay and enzyme immunoassay (EIA). The analysis was performed by sanofi pasteur in a central laboratory . For the neutralization assay, serial 2-fold dilutions of heat inactivated serum samples were mixed with RSV-A and guinea pig complement and incubated with Vero cells in 96-well plates. After 4 days, cells were washed and fixed; mouse anti-RSV F protein monoclonal antibody was added, followed by enzyme-conjugated anti-mouse immunoglobulin. After incubation, the plates were developed with a colorimetric substrate and read on a spectrophotometer. The RSV neutralizing antibody (NA) titer was defined as the log 2 of the inverse dilution of serum that resulted in a 60% reduction in absorbance value when compared with the mean absorbance value of wells that contained virus alone .
For the EIA, the levels of RSV F-specific, RSV G-specific, and nucleocapsid (N)-specific antibodies were determined by coating microtiter plates with purified RSV antigens and incubating the plates with serial 2-fold dilutions of serum samples. Titers were defined by comparison to a reference standard antiserum.
Influenza serologic analysis. Hemagglutinin-inhibition (HAI) antibody assays for H1N1, H3N2, and influenza B vaccine strains were performed in the laboratory of one of the authors (S.G.), by use of standard methodology (hemagglutination-inhibition test for influenza viruses; World Health Organization Collaborating Center for Influenza, Biological Products Division).
Reverse-transcriptase polymerase chain reaction (RT-PCR). Nasal swab samples collected during illnesses were analyzed by RT-PCR for the presence of RSV and influenza A and B RNA. RT-PCR for RSV was performed in the laboratory of one of the authors (A.R.F.), by use of real-time, nested RT-PCR, as described elsewhere [18] . A multiplex RT-PCR for influenza A, B, and RSV was performed in the laboratory of another author (M.Z), as described elsewhere [19] .
Definition of viral infection. RSV infection was defined as a positive RT-PCR result from either laboratory and/or observation of a 4-fold increase in RSV anti-N antibody titer (N protein was not in vaccine) when acute-phase and convalescentphase serum samples were compared. Influenza infection was defined as a positive RT-PCR result and/or observation of a 4-fold increase in HAI antibody titer when acute-phase and convalescent-phase serum samples were compared.
Statistical Analysis
A sample size of 395 subjects per group was calculated on the basis of noninferiority hypothesis testing that compared the geometric mean titer (GMT) ratio of HAI antibody in groups that received RSV and influenza vaccine and placebo and influenza vaccine, assuming 1-sided significance of 2.5% and Ͼ90% power. The enrollment number of 625 subjects per group was determined also to meet the objectives for analysis of RSV immunogenicity and account for subjects who dropped out. Intention-to-treat (ITT) populations were defined as consisting of subjects who had received study vaccine or placebo and had 1 postvaccination analysis (safety or immunogenicity) performed. One month after the first and second vaccinations, geometric mean HAI antibody titers for each influenza strain and their 95% confidence intervals (CIs) were compared for each of the RSV vaccine groups and the placebo group. Titers from sub- NOTE. Data are no. of subjects. During the 2 years of the study, 187 subjects did not complete the study. Ninety-four voluntarily withdrew, 46 withdrew because of a serious adverse event (SAE), 16 were lost to follow-up, 11 were withdrawn because of protocol violations, 9 were withdrawn by the investigator, 6 experienced unrelated medical events, 4 were withdrawn by the sponsor, and 1 was withdrawn for other reasons. None of the subjects who withdrew because of an SAE were affected by an SAE that the investigators considered related to vaccination. ITT, intention-to-treat; NA, not applicable.
a To be included in the ITT population, subjects had to have been randomized and received the study vaccine or placebo; they also had to have had 1 postvaccination analysis (safety or immunogenicity) performed.
b Completed all planned visits and blood sampling outlined in the protocol. (20) 85 (22) 82 (21) NOTE. Data are no. (%) of subjects, unless otherwise indicated. No significant differences were noted between groups. COPD, chronic obstructive pulmonary disorder; CHF, congestive heart failure.
jects with RSV or influenza illness prior to collection of the 1-month postvaccination serum sample were excluded from analysis.
To demonstrate the lack of RSV vaccine interference with the influenza vaccine, the geometric mean HAI antibody titer for each influenza vaccine strain in the RSV vaccine groups had to be Ͼ67% of the lower limit of the 95% CI for the placebo group at 1 month after vaccination. As a first step in assessing the immunogenicity of the RSV vaccine, the normal distribution of NA titers against RSV-A for the entire volunteer cohort was determined at baseline, and the NA titer defining the 67th percentile (i.e., the top third) was calculated. Acceptable immunogenicity for an RSV vaccine candidate was achieved if Ͼ65% of subjects developed an RSV-A NA titer 1 month after the first and second vaccination that was greater than the 67th percentile of the baseline distribution of titers defined above. For within-group analyses, statistical testing for NA titer against RSV-A was performed by using the paired t test and 95% CI for the ratio of GMTs (between samples obtained prior to vaccination, 1 month after the first vaccination, and after revaccination).
RESULTS
Participants. During year 1, there were 1180 subjects enrolled, which represented 63% of the target enrollment of 1875 subjects. Subjects were randomized to receive adjuvanted RSV vaccine (403 subjects), nonadjuvanted RSV vaccine (388 subjects), or placebo (389 subjects) (table 1). Although the number of subjects enrolled was lower than expected, a minimal drop-out rate in the ITT population allowed for sufficient power to achieve the primary and secondary objectives with Ͼ90% power. In year 2, there were 529 subjects revaccinated, of whom 527 were evaluable in the ITT analysis. Of the subjects enrolled in year 2, there were 257 who received RSV vaccine and 270 who received placebo. There were no significant differences between the study groups with regards to age, sex, race, or underlying medical conditions (table 2) . Overall, the study population had a mean age of 74 years, was primarily white, and Ͼ50% male. Of 1180 subjects, 637 (54%) had received a diagnosis of COPD, and 382 (32%) had received a diagnosis of CHF.
Safety of RSV vaccine candidates. More than half of the participants in each group reported no injection site reaction to either the RSV or influenza vaccines. However, local reactions (redness, swelling, and pain) at the injection site were more common in both RSV vaccine groups than in the placebo group, but were generally mild in nature (table 3) . Moderate to severe local reactions were reported by 47 (13%) of 373 adjuvanted RSV vaccine recipients, 35 (10%) of 362 nonadjuvanted RSV vaccine recipients, and 14 (4%) of 363 placebo recipients. In year 2, moderate to severe local reactions were reported by 33 (13%) of 253 nonadjuvanted RSV vaccine recipients and 8 (3%) of 263 placebo recipients. For both study years, there was no significant difference between the vaccine and placebo groups with respect to rates of systemic reactions or AEs in the 1-month period after vaccination.
In the 1-month period after the first vaccination, 25 SAEs were reported by 13 subjects in the adjuvanted RSV vaccine group, 23 SAEs were reported by 17 subjects in the nonadjuvanted RSV vaccine group, and 20 SAEs were reported by 13 subjects in the placebo group. Only 1 event was considered "probably" related to the study vaccine. The subject who had this reaction had a history of worsening dyspnea for 2-3 years prior to vaccination and experienced an exacerbation of COPD within 4 h of receiving nonadjuvanted RSV vaccine. He was treated with prednisone and bronchodilators, and his intermittent COPD exacerbations continued throughout the study. In year 2, during the 1-month period after vaccination there were 10 SAEs reported by 3 subjects in the nonadjuvanted RSV vaccine group and 4 reported by 3 subjects in the placebo group , none of which were deemed related to the study vaccine. During the entire study period there were 750 SAEs reported, of which 10 were classified as potentially related to the vaccine and 1 reaction's relationship to the vaccine was classified as "unknown." Of those 10 events, 1 was probably related (described above); the others were considered "possibly" related and occurred from 33 to 286 days after vaccination (1 report of arrhythmia, 2 reports of CHF, 1 report of bronchitis, 3 reports of pneumonia, 1 report of lung cancer, and 1 report of COPD exacerbation). A total of 74 subjects died during the study (table 3). All deaths were deemed unrelated to the study vaccines by the investigators, and deaths occurred with equal frequency among the groups. In summary, the safety profile for both the adjuvanted and nonadjuvanted RSV vaccines were clinically acceptable.
Immunogenicity of influenza and RSV vaccines. The primary objective of the study was to evaluate the possibility of the candidate RSV vaccines interfering with licensed trivalent influenza vaccine when administered concomitantly during the 2002-2003 season. There were no statistically significant differences when the mean HAI antibody titers for any of the strains in the RSV vaccines were compared with titer values NOTE. In years 1 and 2, respectively, there were 2 subjects (1 who received adjuvanted RSV vaccine and 1 who received placebo) and 4 subjects (3 who received nonadjuvanted RSV vaccine and 1 who received placebo) who had influenza A illness prior to the time day-28 blood samples were obtained and were excluded from analyses. No significant differences were noted between groups. N values are the no. of subjects in the intention-to-treat population (ITT). CI, confidence interval; GMT, geometric mean titer.
for the placebo groups. The geometric mean HAI antibody titers in both RSV vaccine groups Ͼ67% of the lower limit of the 95% CI for the placebo group at 1 month after vaccination for all strains (table 4). In addition, the percentage of subjects who achieved 2-fold and 4-fold increases in HAI antibody titers and the percentage with protective HAI antibody titers (1:40) at 1 month after vaccination were similar in all groups (data not shown).
The secondary objectives of the study were to determine the immunogenicity of the RSV vaccine candidates and to identify 1 vaccine candidate as superior. Both RSV vaccines were determined to be immunogenic on the basis of predefined criteria. At baseline, NA titers for the entire cohort exhibited a normal distribution, with a log 2 NA titer of 11.2 defining the 67th percentile. In the first year, 303 (77%) of 392 adjuvanted RSV recipients and 298 (79%) of 378 nonadjuvanted RSV vaccine recipients achieved NA titers greater than the 67th percentile of the baseline titers at 1 month after vaccination ( figure 1A-1C ). In the second year, 69% of nonadjuvanted RSV vaccine recipients achieved titers of this same magnitude.
The mean NA titer of the nonadjuvanted vaccine group at 1 month after vaccination was significantly higher than that of the adjuvanted vaccine group (12.5 (table 5) . The nonadjuvanted formulation also demonstrated superiority in terms of the percentage of vaccinees who achieved 2-fold and 4-fold increases in NA titers. In addition, binding antibodies against RSV F and G proteins were higher in the nonadjuvanted vaccine group, compared with the adjuvanted vaccine group. At week 52, the mean titers of NA for the adjuvanted vaccine, nonadjuvanted vaccine, and placebo groups returned to baseline and were similar (10.4 and 10.6, respectively) when compared with the mean titer for the placebo group (9.9). At week 56 (1 month after the second vaccination), a significant increase in mean NA titers was observed in the nonadjuvanted group, although peak titers were not as high as after the first vaccination. Similar to what was observed in year 1, NA titers returned to baseline by the end of the second year.
Respiratory illness surveillance. Acute respiratory illness (ARI) was common in all groups during the 7-month surveillance periods of both study years. During the first year, 526 (45%) of 1169 subjects experienced an ARI. Twenty-nine percent of all ARIs required medical attention and led to a physician visit, an emergency department (ED) visit, or hospitalization. Of the illnesses for which diagnostic testing data was available, RSV infection was diagnosed in 36 (7%) of 492 illnesses during year 1 and in 11 (6%) of 189 illnesses in year 2. In comparison, influenza was diagnosed in 40 (8%) of 492 of illnesses during year 1 and in 20 (11%) of 189 of illnesses in year 2. Two subjects had 2 influenza illnesses during year 1. During year 1, there were 38 influenza infections due to strain A and 2 infections due to strain B; in year 2, all influenza infections were due to strain A. The overall incidence of RSV infection in study subjects (all 3 vaccine groups combined) was 3.1% (36 of 1169 subjects) in year 1 and 2.1% (11 of 527) in year 2 (table 6). In comparison, the incidence of influenza during year 1 was 3.3% (33 of 1169 subjects) and 3.8% (20 of 527) in year 2. NOTE. Value column data are log 2 geometric mean titer (95% confidence interval), unless otherwise indicated. In years 1 and 2, respectively, there were 4 subjects and 1 subject who had RSV illness prior to the time day-28 blood samples were obtained and were excluded from the analyses. N values are the no. of subjects in the intention-to-treat population (ITT). NA, neutralizing antibody. a P ϭ .0001, for all comparisons. b Increase in neutralizing titer observed when acute-phase and convalescent-phase serum samples were compared. P ϭ .0006, adjuvanted RSV vs. nonadjuvanted RSV vaccine recipients; P ϭ .0001, all other comparisons.
c Increase in neutralizing titer observed when acute-phase and convalescent-phase serum samples were compared. P ϭ .001, adjuvanted RSV vs. nonadjuvanted RSV vaccine recipients; P ϭ .0001, all other comparisons.
d Neutralizing antibody titer 1 month after the first and second vaccination that was greater than the 67th percentile of the baseline distribution of titers. P ϭ .7, adjuvanted RSV vs. nonadjuvanted RSV vaccine recipients; P ϭ .0001, all other comparisons.
e P ϭ .007, neutralizing antibody titer in adjuvanted RSV vs. nonadjuvanted RSV vaccine recipients; P ϭ .004, anti-F antibody in nonadjuvanted RSV vaccine vs. placebo recipients; P ϭ .0001, all other comparisons.
Among the subjects with laboratory-confirmed viral infection in years 1 and 2, the percentage of patients seeking medical attention for RSV infection was 69% (25 subjects) and 55% (6 subjects), respectively, and for influenza, the percentages were 59% (22 subjects) and 70% (14 subjects), respectively. However, the absolute number of such events was low. Four (11%) of 36 RSV-infected subjects and 6 (16%) of 38 influenza-infected subjects were hospitalized in year 1; none of the 11 RSV-infected subjects and 1 (5%) of 20 influenza-infected subjects were hospitalized in year 2. In total, 4 (8.5%) of 47 RSV-infected subjects and 7 (12.0%) of 58 influenza-infected subjects required hospitalization that was temporally related to their illnesses.
Although the present study was not powered to evaluate vaccine efficacy, an analysis of the incidence of RSV-related ARI and RSV-related ARI requiring medical attention was performed (table 6). No significant difference was found in either the rate of infection or the rate of medically attended RSV disease for either vaccine group, compared with rates in the placebo group. In year 1, there was a trend toward a lower percentage of RSV-infected subjects with severe disease (i.e., illness that required an ED visit or hospitalization) in the RSV vaccine groups, (2 [8.7%] 23 ) compared with the placebo group (3 [22.0%] 13, although this difference was not statistically significant. Notably, the likelihood ratio for RSV-related ARI based on the 1 month postvaccination NA titers in the ITT group suggested an inverse relationship between RSV NA titer and risk of infection. In year 1, the likelihood ratio of RSV-related ARI was 2.9 for those with titers Ͻ9.01; it was 0.86 for those with titers between 11.1 and 12.0; and 0.22 for those with titers Ͼ13.0. A similar but weaker trend was observed in year 2 and was presumed to be the result of fewer RSV-related illnesses.
DISCUSSION
This phase II clinical study demonstrates that concomitant administration of influenza and RSV vaccines did not interfere with the humoral response to influenza vaccine. Furthermore, this candidate RSV vaccine that contains the F, G, and M proteins is safe and immunogenic in older adults who have underlying cardiopulmonary disease. Despite the lack of a specific antibody titer to define protection against RSV illness, the current literature supports the concept that high levels of serum antibody are beneficial [20] . Animal data, observational studies in infants, and the protective effect of humanized monoclonal an- tibody indicate that antibody is important during primary infection and can protect against lower airway disease [15, 16, [21] [22] [23] [24] [25] . In young adults, the ability to be infected with RSV during experimental challenge is associated with low serum levels of NA [26] . In addition, low serum levels of NA correlate with risk of infection and hospitalization in studies of natural infection in elderly adults [11, 12] . Although it is possible that antibody is not causally related to protection, in composite these data suggest that a vaccine that induces high serum levels of NA may be beneficial in adults. Because all adults have measurable antibody to RSV and responses to vaccination have correlated directly with prevaccination titers in prior RSV vaccine studies, we chose to evaluate this vaccine in terms of the percentage of subjects who achieved high levels of NA that might be expected to be relatively protective [21, [27] [28] [29] . On the basis of studies of natural infection, and assuming a threshold exists that serum antibody levels are unlikely to exceed, we chose the 67th percentile of baseline titers in an elderly population as a target to judge immunogenicity [30, 31] . After vaccination with either RSV vaccine formulation, nearly 80% of vaccinees developed titers that exceeded this target level of antibody. The reason for the inferior immunogenicity of the alum-adjuvanted vaccine is unclear, but it may have been related to the degree of adsorption of the antigens to alum [32] . Although vaccination induced significant increases in NA levels, titers in both vaccine groups returned to near baseline levels at 52 weeks. This was expected because similar decay in antibody titers has been observed after natural infection with RSV in adults [33] . Overall, both vaccine formulations elicited a satisfactory humoral response in this elderly, chronically ill population; however, antibody decay suggests that yearly vaccination would likely be necessary.
Although the study was neither designed nor powered to assess efficacy, subjects were monitored for RSV-related illness. In the current study, the incidence of infection and medically attended RSV disease was not different in the RSV vaccine recipients, compared with the placebo group. However, the trend towards a decrease in serious disease (i.e., illness that required an ED visit or hospitalization) in the vaccine groups, compared with placebo recipients (2 [9%] of 22 vs. 3 [23%] of 13), in year 1 and the relationship of postvaccination serum antibody levels with risk of infection provide encouragement that the current vaccine might be efficacious.
Overall, the rates of RSV infection during the current study were relatively low at 2.1%-3.1% of the cohort each season. Although all patients were vaccinated for influenza, it is notable that rates of influenza (3.3%-3.8%) during the same period were comparable to those observed for RSV. In addition, the percentage of RSV and influenza illnesses resulting in hospitalization were similar at 8.5% (4 of 47) and 12.1% (7 of 58), respectively. These data are consistent with estimates of disease burden in adults based on statistical modeling, as well as prospective studies that used specific viral diagnoses [4 -8, 34, 35] . Investigators at the Centers for Disease Control and Prevention estimate that RSV accounts for approximately 11,000 deaths in persons Ͼ65 years old each year, compared with 44,000 yearly deaths due to influenza [4] . In addition, approximately 177,000 adult hospitalizations due to RSV occur each year, compared with 294,000 due to influenza [8, 36] . Thus, although incidence rates of RSV infection are relatively low, the total burden of RSV disease in adults is substantial.
The current study found that this subunit RSV vaccine candidate is safe, immunogenic and does not interfere with humoral response to influenza vaccine in elderly persons with high-risk cardiopulmonary conditions. If higher serum levels of RSV antibody are beneficial, as observational studies suggest, this vaccine offers potential benefit to older adults who are at risk for serious RSV disease. The expanding elderly population in developed countries and the large burden of RSV disease make further development of an RSV vaccine for high-risk adults worthwhile. However, the relatively low incidence of disease presents a formidable challenge for the design and implementation of a vaccine efficacy trial.
